Literature DB >> 30650995

Alizarin increase glucose uptake through PI3K/Akt signaling and improve alloxan-induced diabetic mice.

Lanting Xu1,2, Meimei Xing1,2, Xiaoqing Xu2, Fatma Sa Saadeldeen2, Zhenhua Liu1,2, Jinfeng Wei1,2, Wenyi Kang1,2.   

Abstract

AIM: Alizarin (AZ), that can be isolated from Rubia cordifolia, has biological activities such as antioxidation and anti-inflammatory. This study aimed to investigate the effect of AZ on glucose and lipid metabolism disorders in alloxan-induced diabetic mice and also explored the effect of AZ on insulin resistance in 3T3-L1 adipocytes.
RESULTS: The research showed that AZ could decrease fasting and postprandial blood glucose, TG, TC and MDA, and it could also increase liver glycogen levels and SOD activity in diabetic mice. AZ could significantly improve the glucose uptake of 3T3-L1 adipocytes under insulin resistance, and could also increase GLUT4 protein expression levels, IRS-1 and Akt protein phosphorylation.
CONCLUSION: These results showed that AZ has the potential to reduce blood sugar and improve insulin resistance.

Entities:  

Keywords:  3T3-L1; IRS-1/PI3K/Akt; alizarin; diabetes; insulin resistance

Year:  2019        PMID: 30650995     DOI: 10.4155/fmc-2018-0515

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  3 in total

1.  Study on the Effects of Chinese Materia Medica Processing on the Hypoglycemic Activity and Chemical Composition of Anemarrhenae Rhizoma.

Authors:  Ying-Qi Yu; Li Yan; Xiao-Ting Wang; Li Li; Wei Zheng; Hui Gao
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-19       Impact factor: 2.629

Review 2.  A comprehensive review of Rubia cordifolia L.: Traditional uses, phytochemistry, pharmacological activities, and clinical applications.

Authors:  Min Wen; Qi Chen; Wang Chen; Jing Yang; Xiaogang Zhou; Chunxiang Zhang; Anguo Wu; Jia Lai; Jianping Chen; Qibing Mei; Shuo Yang; Cai Lan; Jianming Wu; Feihong Huang; Long Wang
Journal:  Front Pharmacol       Date:  2022-09-09       Impact factor: 5.988

3.  A Network Pharmacology Approach to Investigate the Mechanism of Erjing Prescription in Type 2 Diabetes.

Authors:  Jiexin Wang; Haiqing Chu; Hangying Li; Wenqian Yang; Yu Zhao; Tong Shen; John Cary; Liming Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-24       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.